LOXL2 inhibitor (Rappaport)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLOXL2 inhibitor (Rappaport)
Drug Alias Namelysyl oxidase homolog 2 inhibitor (Rappaport)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysyl oxidase homolog 2 inhibitors
TargetsLysyl oxidase homolog 2
Therapy Area/IndicationsFibrosisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesBioRap Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBioRap Technologies LtdRappaport Family Institute for Research in the Medical Sciences
Active IndicationsN/A
Inactive IndicationsFibrosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A